Founded on September 28, 2005 through the merger of Daiichi Pharmaceutical and Sankyo, Daiichi Sankyo delivers innovative products that enhance the lives of millions of people around the world. Our recent successes include the antihypertensive agent olmesartan (OlmetecŽ), launched in 2002 by Sankyo and now available in more than 20 countries around the world; the antiplatelet agent prasugrel (EfientŽ), launched in 2009 for patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI); and edoxaban (LixianaŽ), the first available factor Xa inhibitor in Japan, which launched in 2011 to help prevent venous thromboembolism (VTE). Daiichi Sankyo is based in Tokyo and today has 50 billion yen in capital. Source
No articles found.
Galapagos develops therapies with proprietary, novel modes-of-action. Filgotinib, ...
Galapagos develops therapies with proprietary, ...
Abiomed (NASDAQ: ABMD) is a leading provider of medical devices that provide circu...
Abiomed (NASDAQ: ABMD) is a leading provider of...
We are an innovative clinical-stage biopharmaceutical company primarily focused on...
We are an innovative clinical-stage biopharmace...
Although intended for the lungs, many drugs are not given via the airway because d...
Although intended for the lungs, many drugs are...
Esperion is a pharmaceutical company passionately committed to developing and comm...
Esperion is a pharmaceutical company passionate...
Galmed is a clinical-stage biopharmaceutical company focused on the development of...
Galmed is a clinical-stage biopharmaceutical co...
Shockwave Medical, headquartered in Santa Clara, California is a medical device co...
Shockwave Medical, headquartered in Santa Clara...
Join the National Investor Network and get the latest information with your interests in mind.